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are sometimes associated with pneumonectomy but sel-
dom seen after lobectomy. Therefore pneumonectomy
itself is thought to be a disease. Sleeve lobectomy, which
allows preservation of functional lung parenchyma with
the possible advantages of lower mortality and morbidi-
ty, is a valid alternative to pneumonectomy and is
accepted as one of the standard treatments for lung can-
cer.1-3 We therefore have performed it frequently and
actively in noncompromised patients or in patients with
N2 disease.4,5 However, the long-term results after
sleeve lobectomy remain controversial, especially in
relation to nodal involvement. There have been only a
few studies in which sleeve lobectomy and pneumonec-
tomy have been compared with regard to survival
according to nodal status, and the number of patients in
the subgroup related to nodal status was small.3,6
We have reviewed our experience to compare sleeve
lobectomy and pneumonectomy for non–small cell lung
Pneumonectomy, as compared with lobectomy, isassociated with higher occurrence of postoperative
complications, poor quality of life, and cardiopulmonary
dysfunction. In addition, long-term complications (ie,
the so-called postpneumonectomy syndrome presenting
as late pulmonary hypertension or respiratory failure)
Objective: The purpose of this study was to compare the outcomes after
sleeve lobectomy and pneumonectomy for patients with non–small cell lung
cancer distributed according to their nodal involvement status.
Methods: Of 1172 patients in whom primary non–small cell lung carcinoma,
including mediastinal lymph nodes, was completely excised, 151 patients
underwent sleeve lobectomy and 60 underwent pneumonectomy. For bias
reduction in comparison with a nonrandomized control group, we paired 60
patients undergoing sleeve lobectomy with 60 patients undergoing pneu-
monectomy by using the nearest available matching method.
Results: The 30-day postoperative mortality was 2% (1/60) in the pneu-
monectomy group and 0% in the sleeve lobectomy group. Postoperative
complications occurred in 13% of patients in the sleeve lobectomy group and
in 22% of those in the pneumonectomy group. Local recurrences occurred in
8% of patients in the sleeve lobectomy group and in 10% of those in the
pneumonectomy group. The overall 5- and 10-year survivals for the sleeve
lobectomy group were 48% and 36%, respectively, whereas those for the
pneumonectomy group were 28% and 19%, respectively (P = .005).
Multivariable analysis showed that the operative procedure, T factor, and N
factor were significant independent prognostic factors and revealed that sur-
vival after sleeve lobectomy was significantly longer than that after pneu-
monectomy (P = .03).
Conclusions: These data suggest that sleeve lobectomy should be performed
instead of pneumonectomy in patients with non–small cell lung cancer
regardless of their nodal status whenever complete resection can be achieved
because this is a lung-saving procedure with lower postoperative risks and is
as curative as pneumonectomy. (J Thorac Cardiovasc Surg 2000;119:814-9)
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cancer in terms of survival and to determine significant
factors related to survivals with special emphasis on
nodal involvement.
Patients and methods
Of 1370 patients who underwent operation for primary
non–small cell lung cancer between June 1984 and December
1998, 1172 patients underwent curative surgery. Curative
surgery was defined as complete removal of ipsilateral hilar and
mediastinal lymph nodes together with the primary tumor.
Sleeve lobectomy was done in 151 patients, standard (non-
sleeve) lobectomy in 815, segmentectomy in 176, and pneu-
monectomy in 60. Sleeve lobectomy was usually done by
choice in patients who would have been able to tolerate pneu-
monectomy but in whom the tumor could not have been
removed by standard lobectomy and could be completely
resected by a bronchoplastic procedure. Concomitant sleeve
resection of the pulmonary artery (double sleeve resection) was
required in 21 patients. Routine systematic dissection of all hilar
and mediastinal nodes was performed in every case, even if the
preoperative evaluation was N0 or N1. Every node dissected en
bloc (not sampled) was examined by pathologists to be diag-
nosed as microscopically positive (cancerous) or negative (nor-
mal) during and after the operation. Patients who had evidence
of residual tumor at the surgical margin, malignant effusion, or
N3 disease verified by intraoperative findings or postoperative
pathologic examination were considered to have undergone
noncurative surgery7 and were excluded from this study. Local
recurrence was defined as any recurrence in the ipsilateral
hemithorax. Operative mortality was defined as 30-day postop-
erative mortality plus intraoperative mortality. Resected speci-
mens were examined histopathologically, and histologic typing
was done according to the World Health Organization classifi-
cation.8 Surgical-pathologic staging was performed according
to the New International Staging System for Lung Cancer.9
To reduce the bias in the comparison of a nonrandomizcd
control group, we paired the sleeve lobectomy group with the
pneumonectomy group by using the nearest available match-
ing method on the estimated propensity score.10 Table I
shows the characteristics of sleeve lobectomy and pneu-
monectomy groups. Categoric variables were analyzed by
means of χ2 analysis and the unpaired t test. Survival was
estimated by means of the Kaplan-Meier method,11 and dif-
ferences in survival were determined by means of log-rank
analysis. The results of the multivariable analysis of indepen-
dent prognostic factors, which included sex, histologic type,
T factor, N factor, and operative procedure, were assessed by
using the Cox proportional hazards regression model.12 Zero
time was the date of pulmonary resection, and the terminal
event was death attributable to cancer, a cause other than can-
cer, or an unknown cause. Operative mortality was included.
Results
Overall follow-up ranged from 9 to 174 months, with
a median of 69 months. No patients with sleeve lobec-
tomy died within 30 days after the operation, and one
patient with pneumonectomy died of pulmonary infarc-
tion on the day after the operation (operative mortality,
2%). Early postoperative complications occurred in
10% (6/60) of the patients after sleeve lobectomy, con-
sisting of pneumonia-atelectasis (n = 3), empyema (n =
1), pulmonary vein thrombosis (n = 1), and myocardial
infarction (n = 1).
As late complications after sleeve lobectomy, 2 (3%)
patients had bronchial stricture, but they were both suc-
cessfully treated with a bronchoscope and did not
necessitate any operative repair, such as repeat sleeve
resection or completion pneumonectomy. On the other
hand, morbidity after pneumonectomy occurred in
22% (13/60) of the patients, consisting of pneumonia-
atelectasis (n = 5), bronchopleural fistula (n = 4), car-
diac herniation (n = 2), empyema (n = 1), and pul-
monary infarction (n = 1).
Local recurrence developed in 5 (8%) patients after
sleeve lobectomy and in 6 (10%) patients after pneu-
monectomy.
The 3-, 5-, and 10-year survivals were 61%, 48%,
and 36% for patients subjected to sleeve lobectomy
and 36%, 29%, and 19% for those subjected to pneu-
monectomy, respectively (Fig 1). Survival after sleeve
lobectomy was significantly longer than that after
Table I. Sleeve lobectomy and pneumonectomy
groups paired by the nearest available matching
method on the estimated propensity score
Sleeve lobectomy Pneumonectomy P value
No. 60 60
Sex .8
Male 52 (87%) 53 (88%)
Female 8 (13%) 7 (12%)
Age* 60.9 ± 9.5 60.6 ± 9.0 .9
Histologic type .9
SQ 36 (60%) 34 (57%)
AD 21 (35%) 21 (35%)
AS 2 (3%) 3 (5%)
LA 2 (3%) 2 (3%)
pT factor .7
T1 12 (20%) 10 (17%)
T2 19 (32%) 18 (30%)
T3 19 (32%) 17 (28%)
T4 10 (17%) 15 (25%)
pN factor .9
N0 14 (23%) 12 (20%)
N1 16 (27%) 17 (28%)
N2 30 (50%) 31 (52%)
SQ, Squamous cell carcinoma; AD, adenocarcinoma; AS, adenosquamous car-
cinoma; LA, large cell carcinoma.
*Mean ± SD.
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pneumonectomy (P = .005). Among patients with N0
or N1 disease, the 3-, 5-, and 10-year survivals were
82%, 70%, and 55% for patients subjected to sleeve
lobectomy and 50%, 42%, and 29% for patients who
underwent pneumonectomy, respectively (Fig 2). A
significant difference between the operative proce-
dures was found among patients with N0 or N1 dis-
ease (P = .02). On the other hand, among patients
with N2 disease, the 3- and 5-year survivals were 36%
and 21% for patients who underwent sleeve lobecto-
my and 23% and 16% for those subjected to pneu-
monectomy, respectively (Fig 3). Among patients
with N2 disease, there was a trend toward signifi-
cance, although there was no significant difference (P
= .09). Table II shows the results of the multivariable
analysis of independent prognostic factors in patients
with sleeve lobectomy or pneumonectomy, demon-
strating that patients subjected to sleeve lobectomy
had a significantly longer survival than those who
underwent pneumonectomy (P = .03). In addition, T
Fig 1. Cumulative survival curves of all patients who underwent complete resection for non–small cell lung can-
cer according to procedure. The survival of patients subjected to sleeve lobectomy was significantly longer than
that of patients subjected to pneumonectomy (P = .005).
Fig 2. Cumulative survival curves of patients with pN0 or pN1 disease who underwent complete resection for
non–small cell lung cancer according to procedure. Patients in the sleeve lobectomy group survived significant-
ly longer than those in the pneumonectomy group (P = .02).
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factor (P = .03) and N factor (P = .002) were shown
to be significantly related to survival, and the latter
factor affected survival most significantly.
Discussion
In considering bronchoplasty for selected patients
with resectable malignant tumors, we should remember
that the decision to perform this procedure depends on
an appropriate balance between risks of recurrence plus
postoperative complications and postoperative quality
of life. Although bronchoplastic procedures were
shown to be adequate for about 5% to 8% of patients
with a resectable pulmonary malignant tumor,13,14 we
could perform sleeve lobectomy in 13% (151/1172) of
our patients. Because we always keep lung-saving pro-
cedures in mind,4,5,15,16 pneumonectomy was carried
out infrequently compared with sleeve lobectomy. In
fact, the frequency of pneumonectomy in our series
was low (60/1172 [5%]). Instead, we have performed
bronchoplasty frequently and actively not only in com-
promised patients but also in noncompromised
patients. The reconstructed lobes contribute to postop-
erative lung function,15 and if a second primary lung
tumor develops, subsequent resection can be offered.4
We have tried various atypical bronchoplasties, such as
complex extended sleeve lobectomy involving anasto-
mosis between the main and segmental bronchi with
resection of the lobe plus segment, with the purpose of
avoiding pneumonectomy.17
In any case it is important to keep a macroscopically
sufficient margin of safety and to obtain a rapid-frozen
section intraoperatively. A major concern regarding
bronchoplasty for malignancy might be the potentially
increased incidence of local recurrence. The local
recurrence after sleeve lobectomy was 13% in the
review of Tedder and colleagues,13 23% in the series of
Fig 3. Cumulative survival curves of patients with pN2 disease who underwent complete resection for non–small
cell lung cancer according to procedure. Patients in the sleeve lobectomy group tended to survive longer than
those in the pneumonectomy group (P = .09).
Table II. Multivariable analysis of prognostic factors among patients undergoing sleeve lobectomy or pneumonectomy
Characteristics
Factors Unfavorable Favorable Risk ratio 95% CI P value
Sex Male Female 1.11 0.50–2.47 .8
Histologic type non-SQ SQ 1.46 0.90–2.37 .1
pT status T3,4 T1,2 1.74 1.03–2.93 .03
pN status N2 N0,1 2.30 1.35–3.92 .002
Procedure PN SL 1.73 1.05–2.85 .03
CI, Confidence interval; SQ, squamous cell carcinoma; PN, pneumonectomy; SL, sleeve lobectomy. SQ included patients having pure squamous disease, whereas
non-SQ included all other patients, including some with a mixture of cell types, such as adenosquamous carcinoma.
the same, which could affect the survival. In addition,
the poor survival of patients with pneumonectomy
might be due to functional or non–cancer-related rea-
sons. This study demonstrated that sleeve lobectomy
was a suitable surgical treatment for non–small cell
lung cancer in terms of both operative risks and cur-
ability to say nothing of postoperative pulmonary func-
tion. We suggest that sleeve lobectomy should be per-
formed for centrally located lung cancer whenever
removal of the lesions is complete because this proce-
dure accomplished a curability comparable with that of
pneumonectomy, with the possible advantages of lower
operative mortality and morbidity, equal if not better
survival, and improved quality of life.
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Mehran and colleagues,1 and 20% in the report of Van
Schil and colleagues.2 Local recurrence after sleeve
lobectomy was found in 8% of our patients. Compared
with pneumonectomy (10%), sleeve lobectomy was not
associated with an increase in local recurrence.
The operative mortality for sleeve lobectomy in the
review of Tedder and colleagues13 was 6%, and it was
2% in the series of Mehran and colleagues.1 In our
series no operative deaths occurred after sleeve lobec-
tomy compared with 2% operative deaths after pneu-
monectomy. The rate of postoperative complications
was lower after sleeve lobectomy (13%) than after
pneumonectomy (22%). These data thus indicated the
superiority of sleeve lobectomy over pneumonectomy.
Pneumonectomy, which limits pulmonary reserve and
results in an increased pulmonary artery pressure, leads
to greater long-term cardiopulmonary disability and a
worse quality of life than does lobectomy.18 Also,
pneumonectomy has been considered to be a predis-
posing, although not exclusively causative, factor for
cardiopulmonary death.19 We therefore consider that
pneumonectomy is a disease in itself and should be
avoided at all cost.
The relationship between survival after sleeve lobec-
tomy and nodal involvement remains controversial. In
our multivariable analysis, nodal status was the most
significant factor related to survival, with N2 disease
having a definitely negative effect compared with N0
or N1 disease. Mehran and colleagues1 demonstrated a
significant difference in survival between N1 and N2
disease but not between N0 and N1 disease after sleeve
resection and reported acceptable long-term prognosis
in patients undergoing sleeve resection for lung cancer
with N1 disease but not with N2 disease. Although the
5-year survival for patients with N2 disease after sleeve
resection was shown to be 0% by Mehran and col-
leagues,1 it was 33% in the series of Naruke20 and 31%
in the report of Van Schil and colleagues.2 The indica-
tion of sleeve lobectomy for patients with N2 disease
(stage IIIA) is controversial and requires circumspec-
tion. We, however, do not think that pneumonectomy
instead of sleeve lobectomy would have resulted in
longer survival for patients with N2 disease because the
cause of death in patients with N2 disease was mainly
distant metastasis and not local recurrence.
Our multivariable analysis revealed that patients sub-
jected to sleeve lobectomy could have a significantly
better prognosis than those subjected to pneumonecto-
my regardless of sex, histologic type, pN factor, or pT
factor. It was possible that patients who underwent
pneumonectomy would have bigger more central
tumors or more nodes involved, even if the stage was
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